.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The development of direct-acting antiviral combinations transformed chronic hepatitis C treatment. Modern regimens achieve sustained virologic response in the overwhelming majority of appropriately selected patients, usually with short oral courses and far fewer adverse effects than historical interferon-based therapy. For internists, the key clinical opportunity is case finding: many infected individuals remain undiagnosed because chronic hepatitis C can be asymptomatic for years. Once infection is confirmed, fibrosis assessment, drug-interaction review and selection of an appropriate pangenotypic regimen can be coordinated with specialist input when required. Cure reduces the risk of progressive liver disease and hepatocellular carcinoma, although patients with established cirrhosis still require ongoing surveillance. The broader public-health lesson is that effective therapy does not eliminate the need for screening and linkage to care. APICON's hepatology track therefore intersects with internal medicine at multiple levels—from recognizing abnormal liver enzymes to managing metabolic and infectious contributors to chronic liver disease.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The development of direct-acting antiviral combinations transformed chronic hepatitis C treatment. Modern regimens achieve sustained virologic response in the overwhelming majority of appropriately selected patients, usually with short oral courses and far fewer adverse effects than historical interferon-based therapy. For internists, the key clinical opportunity is case finding: many infected individuals remain undiagnosed because chronic hepatitis C can be asymptomatic for years. Once infection is confirmed, fibrosis assessment, drug-interaction review and selection of an appropriate pangenotypic regimen can be coordinated with specialist input when required. Cure reduces the risk of progressive liver disease and hepatocellular carcinoma, although patients with established cirrhosis still require ongoing surveillance. The broader public-health lesson is that effective therapy does not eliminate the need for screening and linkage to care. APICON's hepatology track therefore intersects with internal medicine at multiple levels—from recognizing abnormal liver enzymes to managing metabolic and infectious contributors to chronic liver disease.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
